• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改变的染色质景观和增强子结合是 MED12 突变型子宫平滑肌瘤中转录失调的基础。

Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.

机构信息

Driskill Graduate Program in Life Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Department of Obstetrics and Gynecology, Division of Reproductive Science in Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

出版信息

Nat Commun. 2020 Feb 24;11(1):1019. doi: 10.1038/s41467-020-14701-6.

DOI:10.1038/s41467-020-14701-6
PMID:32094355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7040020/
Abstract

Uterine leiomyomas (fibroids) are a major source of gynecologic morbidity in reproductive age women and are characterized by the excessive deposition of a disorganized extracellular matrix, resulting in rigid benign tumors. Although down regulation of the transcription factor AP-1 is highly prevalent in leiomyomas, the functional consequence of AP-1 loss on gene transcription in uterine fibroids remains poorly understood. Using high-resolution ChIP-sequencing, promoter capture Hi-C, and RNA-sequencing of matched normal and leiomyoma tissues, here we show that modified enhancer architecture is a major driver of transcriptional dysregulation in MED12 mutant uterine leiomyomas. Furthermore, modifications in enhancer architecture are driven by the depletion of AP-1 occupancy on chromatin. Silencing of AP-1 subunits in primary myometrium cells leads to transcriptional dysregulation of extracellular matrix associated genes and partly recapitulates transcriptional and epigenetic changes observed in leiomyomas. These findings establish AP-1 driven aberrant enhancer regulation as an important mechanism of leiomyoma disease pathogenesis.

摘要

子宫平滑肌瘤(纤维瘤)是育龄妇女妇科发病率的主要原因,其特征是细胞外基质过度沉积,导致僵硬的良性肿瘤。尽管转录因子 AP-1 的下调在平滑肌瘤中非常普遍,但 AP-1 缺失对子宫纤维瘤中基因转录的功能后果仍知之甚少。本研究采用高分辨率 ChIP-seq、启动子捕获 Hi-C 和匹配的正常和平滑肌瘤组织的 RNA-seq,结果表明,修饰的增强子结构是 MED12 突变型子宫平滑肌瘤转录失调的主要驱动因素。此外,增强子结构的修饰是由染色质上 AP-1 占据的缺失驱动的。在原代子宫平滑肌细胞中沉默 AP-1 亚基会导致细胞外基质相关基因的转录失调,并部分再现平滑肌瘤中观察到的转录和表观遗传变化。这些发现确立了 AP-1 驱动的异常增强子调控作为平滑肌瘤疾病发病机制的重要机制。

相似文献

1
Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.改变的染色质景观和增强子结合是 MED12 突变型子宫平滑肌瘤中转录失调的基础。
Nat Commun. 2020 Feb 24;11(1):1019. doi: 10.1038/s41467-020-14701-6.
2
Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.通过全外显子组测序和全基因组芯片分析子宫平滑肌瘤高度异质性的基因组格局
Fertil Steril. 2017 Feb;107(2):457-466.e9. doi: 10.1016/j.fertnstert.2016.10.035. Epub 2016 Nov 23.
3
Epigenomic and enhancer dysregulation in uterine leiomyomas.子宫平滑肌瘤中的表观基因组和增强子失调。
Hum Reprod Update. 2022 Jun 30;28(4):518-547. doi: 10.1093/humupd/dmac008.
4
Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.与子宫平滑肌瘤相关的MED12突变会破坏与中介体相关的CDK活性。
Cell Rep. 2014 May 8;7(3):654-60. doi: 10.1016/j.celrep.2014.03.047. Epub 2014 Apr 18.
5
MED12 mutation frequency in unselected sporadic uterine leiomyomas.未选择的散发性子宫平滑肌瘤中 MED12 突变的频率。
Fertil Steril. 2014 Oct;102(4):1137-42. doi: 10.1016/j.fertnstert.2014.06.040. Epub 2014 Aug 6.
6
MED12 exon 2 mutations in histopathological uterine leiomyoma variants.MED12 外显子 2 突变与组织病理学子宫平滑肌瘤变异。
Eur J Hum Genet. 2013 Nov;21(11):1300-3. doi: 10.1038/ejhg.2013.33. Epub 2013 Feb 27.
7
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.MED12和HMGA2突变:子宫平滑肌瘤和平滑肌肉瘤中的两个独立遗传事件。
Mod Pathol. 2014 Aug;27(8):1144-53. doi: 10.1038/modpathol.2013.243. Epub 2014 Jan 3.
8
Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.维生素 D 作为一种有效的治疗方法,可用于人类子宫肌瘤,与中介复合物亚基 12 突变无关。
Fertil Steril. 2021 Feb;115(2):512-521. doi: 10.1016/j.fertnstert.2020.07.049. Epub 2020 Oct 7.
9
HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.HMGA2 和 MED12 改变在子宫平滑肌瘤中经常共同发生。
Gynecol Oncol. 2018 Sep;150(3):562-568. doi: 10.1016/j.ygyno.2018.07.007. Epub 2018 Jul 13.
10
Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.外显子1中的突变突出了MED12在子宫平滑肌瘤中的作用。
Hum Mutat. 2014 Sep;35(9):1136-41. doi: 10.1002/humu.22612. Epub 2014 Jul 21.

引用本文的文献

1
ProOvErlap: Assessing feature proximity/overlap and testing statistical significance from genomic intervals.ProOvErlap:评估特征接近度/重叠度并检验基因组区间的统计显著性。
J Biol Chem. 2025 May 8;301(6):110209. doi: 10.1016/j.jbc.2025.110209.
2
Chromatin state origins of uterine leiomyoma.子宫平滑肌瘤的染色质状态起源
Nat Commun. 2025 May 8;16(1):4307. doi: 10.1038/s41467-025-59646-w.
3
MED12 dysregulation: insights into cancer and therapeutic resistance.MED12失调:对癌症及治疗抗性的见解

本文引用的文献

1
H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas.H19 lncRNA 被鉴定为驱动子宫平滑肌瘤的基因的主要调节因子。
Oncogene. 2019 Jul;38(27):5356-5366. doi: 10.1038/s41388-019-0808-4. Epub 2019 May 15.
2
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.Metascape 为系统水平数据集的分析提供了面向生物学家的资源。
Nat Commun. 2019 Apr 3;10(1):1523. doi: 10.1038/s41467-019-09234-6.
3
Identification of human silencers by correlating cross-tissue epigenetic profiles and gene expression.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 19. doi: 10.1007/s00210-025-04006-0.
4
Differential Expression of Small Non-Coding RNAs in Uterine Leiomyomas.子宫平滑肌瘤中小非编码RNA的差异表达
Int J Mol Sci. 2025 Feb 16;26(4):1688. doi: 10.3390/ijms26041688.
5
Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming.介质激酶抑制通过超级增强子重编程驱动子宫肌层干细胞分化和子宫肌瘤表型。
J Mol Med (Berl). 2025 Mar;103(3):311-326. doi: 10.1007/s00109-025-02517-0. Epub 2025 Feb 4.
6
Mediator kinase inhibition drives myometrial stem cell differentiation and the uterine fibroid phenotype through super-enhancer reprogramming.介质激酶抑制通过超级增强子重编程驱动子宫肌层干细胞分化和子宫肌瘤表型。
Res Sq. 2024 Dec 16:rs.3.rs-5125876. doi: 10.21203/rs.3.rs-5125876/v1.
7
Engineered uterine primary myometrial cells with high-mobility group AT-hook 2 overexpression display a leiomyoma-like transcriptional and epigenomic phenotype.高迁移率族蛋白 A2 过表达的工程化子宫原发性平滑肌细胞呈现出类似于平滑肌瘤的转录组和表观基因组表型。
F S Sci. 2024 Nov;5(4):352-368. doi: 10.1016/j.xfss.2024.07.008. Epub 2024 Jul 27.
8
Structures and compositional dynamics of Mediator in transcription regulation.转录调控中介体的结构与组成动力学
Curr Opin Struct Biol. 2024 Oct;88:102892. doi: 10.1016/j.sbi.2024.102892. Epub 2024 Jul 26.
9
Novel insights into the phenotypic spectrum and pathogenesis of Hardikar syndrome.哈迪卡尔综合征表型谱和发病机制的新见解。
Genet Med. 2024 Oct;26(10):101222. doi: 10.1016/j.gim.2024.101222. Epub 2024 Jul 20.
10
Induction of fibrosis following exposure to bisphenol A and its analogues in 3D human uterine leiomyoma cultures.暴露于双酚 A 及其类似物后,3D 人子宫肌瘤培养物中的纤维化诱导。
J Hazard Mater. 2024 Sep 5;476:134772. doi: 10.1016/j.jhazmat.2024.134772. Epub 2024 May 31.
通过关联跨组织表观遗传谱和基因表达鉴定人类沉默子。
Genome Res. 2019 Apr;29(4):657-667. doi: 10.1101/gr.247007.118. Epub 2019 Mar 18.
4
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.转录因子 c-Jun/AP-1 通过调节骨桥蛋白表达促进非酒精性脂肪性肝炎肝纤维化。
Cell Death Differ. 2019 Sep;26(9):1688-1699. doi: 10.1038/s41418-018-0239-8. Epub 2019 Feb 18.
5
Diverse motif ensembles specify non-redundant DNA binding activities of AP-1 family members in macrophages.不同的基序组合特异性地指定了巨噬细胞中 AP-1 家族成员的非冗余 DNA 结合活性。
Nat Commun. 2019 Jan 24;10(1):414. doi: 10.1038/s41467-018-08236-0.
6
Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.得克萨斯州南部西班牙裔女性的 MED12 突变型子宫纤维瘤中的介导体激酶破坏。
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4283-4292. doi: 10.1210/jc.2018-00863.
7
The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia.慢性淋巴细胞白血病的参考表观基因组和调控染色质景观。
Nat Med. 2018 Jun;24(6):868-880. doi: 10.1038/s41591-018-0028-4. Epub 2018 May 21.
8
Enhancers: bridging the gap between gene control and human disease.增强子:连接基因调控与人类疾病的桥梁。
Hum Mol Genet. 2018 Aug 1;27(R2):R219-R227. doi: 10.1093/hmg/ddy167.
9
Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.致癌外显子 2 突变在中介体亚基 MED12 中破坏了细胞周期蛋白 C-CDK8/19 的变构激活。
J Biol Chem. 2018 Mar 30;293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.
10
AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection.AP-1 转录因子和 BAF 复合物介导信号依赖性增强子选择。
Mol Cell. 2017 Dec 21;68(6):1067-1082.e12. doi: 10.1016/j.molcel.2017.11.026.